NVIDIA GTC 2026 highlighted a major shift toward agentic AI, with autonomous systems driving rapid growth in compute demand and transforming industries like healthcare and life sciences. Nvidia emphasized that healthcare is adopting AI at more than twice the rate of other sectors, fueled largely by startups and increasing investment in infrastructure. Large pharmaceutical companies such as Roche and Eli Lilly are scaling AI capabilities through massive GPU deployments and partnerships, while advances in biological reasoning models and protein design are accelerating drug discovery and research productivity.
Within this ecosystem, Hippocratic AI was identified as a key partner contributing to the rise of specialized healthcare agents. The company is developing patient-facing AI agents focused on chronic care management and post-discharge follow-ups, aligning with the broader trend of using agentic systems to support clinical workflows and patient engagement. These efforts reflect a growing movement toward safe, scalable AI applications that augment healthcare delivery, alongside other platforms deploying multi-agent systems to handle complex tasks like clinical trials and medical documentation.